Finance
Net loss reported at CAN$0.34 per share
Published in Vaccine Weekly, September 18th, 2002
Results are reported in Canadian dollars with a June 30, 2002, rate of $1.00 Canadian equaling US$0.66.
Financial results for the 6 months ended June 30, 2002, reflect a consolidated net loss from operations of $15.4 million or $0.34 per share compared with $22.9 million or $0.45 per share, for the same period in 2001. The decreased loss in 2002 is due to an $8.6 million reduction in gross research and development expenditures offset by $1.1 million in market development costs.
Contract research and development revenues for the 6 months...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2002-09-18)
More Articles from Vaccine Weekly
- Cancer Vaccine
Vaccine that targets human chorionic gonadotropin extends colorectal cancer patient survival - Human Papillomavirus
Mumps vaccine induces remission in patients with recurrent respiratory papilloma - Ebola Virus
Vaccine effective in mice with cell-mediated immune function - HIV Prevention
Promising multistrain HIV vaccine candidate emerges - Influenza Vaccine
Interventional program dramatically increases influenza vaccination rates among the elderly - Vaccinia Virus Vaccine
A recombinant vaccinia virus Lister shows promise as a vaccine vector - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
